Imunon, Inc.

Imunon, Inc.

Biotechnology • Healthcare • Lawrenceville, NJ, United States • IMNN (NCM)

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

609 896 9100 997 Lenox Drive, Lawrenceville, NJ 08648, United States

Stock Performance (90 Days)

Data through Dec 30, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Alphabet vs. Microsoft: Better AI Stock to Own in 2026? - The Motley Fool
The Motley Fool • Dec 30
GM's record stock performance beats Tesla, Ford and other automakers in 2025 - CNBC
CNBC • Dec 29
Ovarian cancer drug adds 13 months survival in early trial data - Stock Titan
Stock Titan • Dec 29
Tesla Stock Defied the Odds in 2025. Can It Do It Again in 2026? - Barron's
Barron's • Dec 29
General Motors stock on track to beat auto rivals like Tesla, Ford in 2025 - New York Post
New York Post • Dec 29

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Imunon, Inc. had layoffs?
No layoff events have been recorded for Imunon, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Imunon, Inc. have?
Imunon, Inc. has approximately 25 employees.
What industry is Imunon, Inc. in?
Imunon, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Imunon, Inc. a publicly traded company?
Yes, Imunon, Inc. is publicly traded under the ticker symbol IMNN on the NCM. The company has a market capitalization of approximately $0.01 billion.
Where is Imunon, Inc. headquartered?
Imunon, Inc. is headquartered in Lawrenceville, NJ, United States at 997 Lenox Drive, Lawrenceville, NJ 08648, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.